TF expression on neutrophils from aPL-treated mice depends on C5aR. (A) FACS analysis of TF expression on whole blood neutrophils from aPL-treated mice. The number of TF-positive neutrophils increased in aPL-treated C5aR^+/+ mice in comparison with untreated mice (39% ± 16% vs 4% ± 2%, P < .005). The number of TF-positive neutrophils did not increase in aPL-treated C5aR^−/− mice (9% ± 4%). (B) Immunohistochemical detection of TF on neutrophils from C5aR^+/+ mice treated with aPL-IgG (i), C5aR^−/− mice treated with aPL-IgG (ii), and untreated mice (iii). (C) FACS analysis of TF expression on whole blood neutrophils from aPL-treated mice. The number of TF-positive neutrophils increased in aPL-treated TF^{floxed/floxed} mice in comparison with untreated mice (26% ± 9% vs 7% ± 1%, P < .001). In contrast, the number of TF-positive neutrophils did not increase in TF^{floxed/floxed}/LysM-Cre mice treated with aPL-IgG (6% ± 2%). (D) Immunohistochemical detection of TF on neutrophils from TF^{floxed/floxed} mice treated with aPL-IgG (i), TF^{floxed/floxed}/LysM-Cre mice treated with aPL-IgG (ii), and untreated mice (iii). (E) FACS analysis of ROS production in neutrophils from aPL-treated mice. The number of ROS-positive neutrophils increased in aPL-treated TF^{floxed/floxed} mice in comparison with untreated mice (29% ± 9% vs 5% ± 1%, P < .01). The number of ROS-positive neutrophils did not increase TF^{floxed/floxed}/LysM-Cre mice treated with aPL-IgG (10% ± 3%).